Epizyme (EPZM) Revised Celgene Agreement 'Net Positive', Mizuho Securities Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil falls as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
Epizyme Announces Extension of Celgene Research Collaboration
July 9, 2015 7:00 AM EDTCollaboration to focus on three first-in-class preclinical epigenetic targets Epizyme to receive $10 million extension fee payment and up to $610 million in potential milestones Epizyme extends cash runway through at least the end of the second quarter of 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that it has amended and restated its agreement with Celgene Corporation to extend the research collaboration... More
